Biography

• Wei-feng Shen is an Emeritus Professor of Medicine, chief physician, and doctoral supervisor of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. He was graduated from Shanghai Second Medical University in 1975 and received his Doctor of Medicine degree from the University of Sydney, Australia in 1985. He was the vice president of Ruijin Hospital, and the vice chair of the Cardiovascular Branch of the Chinese Medical Association. He is currently a member of the National Cardiology Expert Committee, director of the Shanghai Cardiac Interventional Quality Control Center, and director of the Institute of Cardiovascular Disease. He is the honorary chairman of the Cardiovascular Branch of the Shanghai Medical Association, and a member of the European, French, and Hong Kong Cardiology Association. He is editor-in-chief of The International Journal of Cardiovascular Diseases, executive editor-in-chief of The Chinese Journal of Interventional Cardiology, deputy editor-in-chief of The Chinese Journal of Medical Science, Chinese Journal of Cardiovascular Disease, and Journal of Interventional Radiology.

• He specializes in interventional cardiology, diagnosis and treatment of high-risk coronary heart disease, heart failure, and valvular heart disease. He has published more than 200 SCI articles and edited more than 10 monographs. He has been awarded the second prize of the National Science and Technology Progress Award, the first prize of the Shanghai Science and Technology Progress Award, the second prize of Chinese Medicine, and the second prize of the Medical Science and Technology Award of the Ministry of Education. He has been awarded the Excellent Returned Overseas Student of the Ministry of Personnel and the Model Worker of the National Health System.

Publications

1. Wu F, Wang HY, Cai F, Wang LJ, Zhang FR, Chen XN, Yang Q, Jiang MH, Wang XF, Shen WF: Valsartan decreases platelet activity and arterial thrombotic events in elderly patients with hypertension. Chin Med J (Engl) 2015, 128(2):153-158.

2. Shen Y, Pu LJ, Lu L, Zhang Q, Zhang RY, Shen WF: Serum advanced glycation end-products and receptors as prognostic biomarkers in diabetics undergoing coronary artery stent implantation. Can J Cardiol 2012, 28(6):737-743.

3. Zhang Q, Zhang RY, Qiu JP, Zhang JF, Wang XL, Jiang L, Liao ML, Zhang JS, Hu J, Yang ZK et al: One-year clinical outcome of interventionalist- versus patient-transfer strategies for primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results from the REVERSE-STEMI study. Circulation Cardiovascular quality and outcomes 2011, 4(3):355-362.

4. Yang ZK, Ying C, Zhao HY, Fang YH, Chen Y, Shen WF: Mineral metabolism disturbances are associated with the presence and severity of calcific aortic valve disease. J Zhejiang Univ Sci B 2015, 16(5):362-369.

5. Zhang Q, Qiu JP, Zhang RY, Hu J, Yang ZK, Ding FH, Du R, Zhu TQ, Zhang JS, Shen WF: Improved outcomes from transradial over transfemoral access in primary percutaneous coronary intervention for patients with acute ST-segment elevation myocardial infarction and upstream use of tirofiban. Chin Med J (Engl) 2013, 126(6):1063-1068.

6. Zhang Q, Zhang RY, Qiu JP, Jin HG, Zhang JF, Wang XL, Jiang L, Liao ML, Hu J, Ding FH et al: Impact of different clinical pathways on outcomes of patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the RAPID-AMI study. Chin Med J (Engl) 2009, 122(6):636-642.

7. Shen Y, Wang XQ, Dai Y, Wang YX, Zhang RY, Lu L, Ding FH, Shen WF: Diabetic dyslipidemia impairs coronary collateral formation: An update. Front Cardiovasc Med 2022, 9:956086.

8. Lu L, Zhang RY, Wang XQ, Liu ZH, Shen Y, Ding FH, Meng H, Wang LJ, Yan XX, Yang K et al: C1q/TNF-related protein-1: an adipokine marking and promoting atherosclerosis. Eur Heart J 2016, 37(22):1762-1771.

9. Wang XQ, Liu ZH, Xue L, Lu L, Gao J, Shen Y, Yang K, Chen QJ, Zhang RY, Shen WF: C1q/TNF-related protein 1 links macrophage lipid metabolism to inflammation and atherosclerosis. Atherosclerosis 2016, 250:38-45.

10. Yang K, Wang XQ, He YS, Lu L, Chen QJ, Liu J, Shen WF: Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells. Cardiovasc Diabetol 2010, 9:66.